<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845688</url>
  </required_header>
  <id_info>
    <org_study_id>ShanghaiSTCSM-2011</org_study_id>
    <secondary_id>11DZ1972703</secondary_id>
    <nct_id>NCT01845688</nct_id>
  </id_info>
  <brief_title>Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy</brief_title>
  <official_title>Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>wanglin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai University of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen
      Granule to treat idiopathic membranous nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour urine protein</measure>
    <time_frame>At the 24thweek</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum albumin concentration</measure>
    <time_frame>At the 24thweek</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR</measure>
    <time_frame>At the 24thweek</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase</measure>
    <time_frame>At the 24thweek</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>T-cell classification</measure>
    <time_frame>At the 24thweek</time_frame>
    <description>Detecting by flow cytometry method</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Idiopathic Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Losartan Tablets &amp; QingReMoShen Granule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan Tablets &amp; Placebo Granule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan Tablets &amp; QingReMoShen Granule</intervention_name>
    <arm_group_label>Losartan Tablets &amp; QingReMoShen Granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan Tablets &amp; Placebo Granule</intervention_name>
    <arm_group_label>Losartan Tablets &amp; Placebo Granule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy;

          -  6.0g≥24 hour urinary protein≥1.0g;

          -  serum albumin concentration≥26g/L;

          -  Chronic Kidney Disease (CKD)≤3 stage (eGFR＞30ml/min/1.73m2 MDRD);

          -  Willing to participate in the trial and signed an informed consent.

        Exclusion Criteria:

          -  Secondary membranous nephropathy;

          -  Patients with one of the following circumstances- malignant tumors or malignancy, HIV
             infection, a history of mental illness, any serious systemic infection, serious
             gastrointestinal diseases, circulating hepatitis B surface antigens positive or
             persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes
             mellitus;

          -  Pregnant and lactating women;

          -  Undergoing other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Wang, PHD,MD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai University of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai University of Traditional Chinese Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai University of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>wanglin</investigator_full_name>
    <investigator_title>Deputy director of Physicians</investigator_title>
  </responsible_party>
  <keyword>Idiopathic Membranous Nephropathy</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>Randomized Control Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

